Exicure, Inc.

What they do

Exicure historically developed nucleic acid therapies but halted R&D in 2022 and sold its historical biotech IP in 2024. In January 2025, it acquired GPCR Therapeutics USA, gaining a clinical-stage program (GPC-100 with propranolol) for stem cell mobilization in multiple myeloma and other hematologic diseases. The company currently has no product revenue and relies on limited cash, royalties, and strategic transactions.

Revenue drivers

• Royalties and license fees — Under the 2024 purchase agreement for its historical biotechnology IP, Exicure may receive modest royalties and license fees, but amounts and timing are uncertain and out of its control.
• Milestone payments from GPCR collaboration — The License and Collaboration Agreement with GPCR requires Exicure to make milestone payments in cash or stock upon clinical, regulatory, and sales milestones; these are obligations, not revenue.
• No product sales — Exicure reported $0 revenue for fiscal 2025 and for all quarters through March 2026; the company currently has no marketed products.

Recent performance

For fiscal 2025, Exicure reported a net loss of $4.9 million, improved from a $9.7 million loss in 2024, primarily due to a $6.0 million gain from early lease termination. R&D expense rose to $3.3 million (from $0) following the GPCR USA acquisition, and G&A expense increased to $6.8 million from $5.4 million. Cash and equivalents were $3.7 million at year-end 2025, down from $12.5 million, and further declined to $2.6 million by March 31, 2026. The company's balance sheet shows total assets of $12.8 million, total liabilities of $10.7 million, and shareholder equity of $2.1 million as of March 31, 2026.

Strategy

Management is actively exploring strategic alternatives, including private company acquisitions, raising capital, and partnerships, to maximize stockholder value. It acquired GPCR USA in January 2025 to obtain a clinical-stage hematology asset and entered a license and collaboration agreement for GPCR's technologies. The company formed a South Korean subsidiary in 2025 but decided to sell it in November 2025, recognizing a loss on disposal. Exicure intends to make a $1.0 million milestone payment to GPCR in stock in Q2 2026 following the Phase 2 trial completion.

Risks

• Going concern risk — Management states existing cash is insufficient to fund operations for the next 12 months, and substantial additional financing is required in the short term.
• Strategic alternative execution risk — The board and management lack meaningful experience in executing strategic transactions in U.S. public markets, and any deal may not deliver expected benefits.
• Nasdaq delisting risk — The company may fail to maintain minimum stockholders' equity and stock price requirements for continued listing on Nasdaq.
• Dependence on GPCR program — The lead asset (GPC-100) is still in clinical development, and future royalties or license fees from the historical IP are uncertain and outside management's control.

Outlook

Management expects to continue exploring strategic alternatives but cautions that no assurance exists of identifying or consummating a transaction. The company anticipates needing to raise capital in the near term to fund operations and any strategic initiatives. A $1.0 million milestone payment to GPCR is planned in Q2 2026, to be settled in common stock.